» Articles » PMID: 36263116

Role of the Multi-drug Efflux Systems on the Baseline Susceptibility to Ceftazidime/avibactam and Ceftolozane/tazobactam in Clinical Isolates of Non-carbapenemase-producing Carbapenem-resistant

Abstract

Carbapenem-resistant (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon.

Citing Articles

Scalable and Chromatography-Free Synthesis of Efflux Pump Inhibitor Phenylalanine Arginine β-Naphthylamide for Its Validation in Wild-Type Bacterial Strains.

Russo C, Howey K, OReilly M ChemMedChem. 2023; 18(14):e202300128.

PMID: 37126222 PMC: 10524873. DOI: 10.1002/cmdc.202300128.

References
1.
Castanheira M, Mills J, Farrell D, Jones R . Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014; 58(11):6844-50. PMC: 4249397. DOI: 10.1128/AAC.03681-14. View

2.
van Duin D, Bonomo R . Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016; 63(2):234-41. PMC: 4928383. DOI: 10.1093/cid/ciw243. View

3.
Mihara T, Kimura T, Momiyama K, Kainuma A, Akiyama K, Ohara J . Secondary in-hospital epidemiological investigation after an outbreak of Pseudomonas aeruginosa ST357. J Infect Chemother. 2019; 26(3):257-265. DOI: 10.1016/j.jiac.2019.09.014. View

4.
de la Rosa J, Nordmann P, Poirel L . ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. 2019; 74(7):1934-1939. DOI: 10.1093/jac/dkz149. View

5.
Pena C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V . Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother. 2011; 56(3):1265-72. PMC: 3294876. DOI: 10.1128/AAC.05991-11. View